TrialThe Journal of rheumatology2017

Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment.

D James Haddon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.